Cognitive decline in adults can be slowed through FDA-approved medications and lifestyle changes that have proven effective in clinical trials. Mild cognitive impairment (MCI)—a decline in memory or thinking skills beyond normal aging but without serious loss of daily function—affects 10–20% of adults aged 65 and older.
The National Institute on Aging identifies MCI as a precursor stage between normal aging and dementia, and catching it early opens access to both medication and behavioral interventions. Effective management combines two approaches: FDA-approved drugs that target amyloid buildup in the brain, and multidomain lifestyle changes addressing exercise, diet, cognitive activity, and cardiovascular health. The evidence shows that combining these strategies offers the best chance of slowing progression.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Mild Cognitive Impairment—How It Differs From Normal Aging
- FDA-Approved Medications That Slow Cognitive Decline
- Lifestyle Interventions—The Evidence for Multidomain Approaches
- Practical Steps You Can Start Now
- When to Seek Evaluation and Treatment
Mild Cognitive Impairment—How It Differs From Normal Aging
MCI is distinct from occasional memory lapses like forgetting a word or where you parked. With MCI, memory or thinking declines noticeably enough to affect work or hobbies—yet you remain independent and functional. This boundary between normal aging and dementia is where MCI sits.
Not everyone with MCI develops dementia. Some people stabilize or improve with intervention. early identification matters because treatments work best when decline is caught in its earliest stages.
FDA-Approved Medications That Slow Cognitive Decline
Two medications target the amyloid buildup underlying early Alzheimer's disease. Both require blood or PET imaging to confirm that amyloid is actually present before treatment starts. Donanemab (Kisunla) received full FDA approval on July 2, 2024. In clinical trials, it slowed cognitive decline by approximately 35% over 18 months compared to placebo—equivalent to delaying progression by 4.5 to 7.5 months. The drug is given as an infusion through a healthcare provider.
Lecanemab (Leqembi) was approved by the FDA in July 2023. A major advancement came in August 2025: a self-injectable home-dosing form received approval, allowing patients to receive treatment at home. Both drugs slow decline by similar magnitude and work only when amyloid is confirmed present. An important limitation: these medications do not reverse cognitive decline. They slow its rate. They also require ongoing medical monitoring and work best for people with early symptoms—MCI or mild dementia—not advanced disease.
Lifestyle Interventions—The Evidence for Multidomain Approaches
The strongest evidence comes from combining multiple brain-health strategies rather than pursuing any single one. The Finnish FINGER trial demonstrated that combining physical exercise, a Mediterranean-like diet, cognitive training, and vascular risk management significantly prevented cognitive decline in older adults at risk. The multidomain approach proved more effective than any single intervention alone. These four pillars work together to protect brain health.
Exercise increases blood flow and supports the growth of new brain cells. A Mediterranean-style diet reduces inflammation and protects the blood vessels supplying the brain. Cognitive training—learning new skills or hobbies demanding sustained attention—strengthens neural networks. Managing cardiovascular risk factors like blood pressure, cholesterol, and blood sugar protects the small vessels in the brain.
Practical Steps You Can Start Now
You don't need perfection. Gradual changes compound over time. For movement: Target at least 150 minutes of moderate activity per week—roughly 30 minutes on most days. Walking, swimming, dancing, or strength training all count. Muscle strength and bone density decline with age; strength training helps preserve both. For eating: Base meals on vegetables, fruits, whole grains, fish, legumes, nuts, and olive oil.
Limit red meat and processed foods. This Mediterranean-style pattern reduces inflammation linked to cognitive decline. For mental engagement: Learn something new that demands sustained focus—a language, instrument, skill, or hobby. Socially engaging activities provide extra protection for cognition. For heart health: Work with your doctor to monitor blood pressure, cholesterol, blood sugar, and weight. Brain blood flow depends on healthy vessels; these factors protect them.
When to Seek Evaluation and Treatment
If you notice memory or thinking changes that concern you, speak with your doctor. MCI is diagnosed through cognitive testing, not by self-report alone. Early evaluation opens access to medication trials (if amyloid is present) and structured lifestyle support.
If you qualify for Donanemab or Lecanemab, your doctor will order imaging to confirm amyloid pathology. Treatment decisions weigh the benefit against the time commitment required and your individual tolerance. If you're not eligible, lifestyle interventions remain your strongest evidence-based option. Either way, discussing progress and monitoring changes regularly with your doctor is essential.
